Ferring launches Lysteda

PARSIPPANY, N.J. Drug maker Ferring Pharmaceuticals has launched a new treatment for women with cyclic heavy menstrual bleeding, Ferring said Monday.

Ferring announced the availability of Lysteda (tranexamic acid) tablets, which it bills as the only non-hormonal and non-surgical therapy for women with cyclic heavy menstrual bleeding. As many as 22 million women in the United States experience HMB.

“Heavy menstrual bleeding is a common condition that can significantly interfere with a woman’s daily activities,” Ferring VP medical affairs Edward Trott said. “Many women consider the condition normal and are unaware that there are treatments available, so they don’t ask their doctor about it.”